IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Taps Dr. Craig Cheifetz as Advisor for Clinical Trials of Cannabis-Based Combination Therapies

India Globalization Capital, Inc. (NYSE MKT: IGC) has named Craig Cheifetz, M.D., as an advisor to aid the company in its clinical trials in microbiology, immunology, neuroscience, and biotechnology. IGC is engaged in the development of cannabis-based therapies, which treat pain, terminal neurological and oncological diagnosis, PTSD, seizures, and other life altering issues. The company, based in Bethesda, Maryland, has a portfolio of patent filings for its phytocannabinoid-based treatments.

In a news release, Ram Mukunda, CEO of IGC, welcomed Cheifetz to the company’s advisory team, noting that he looks forward to Chiefetz’s contributions as IGC develops unique cannabis combination therapies.

Cheifetz is the Medical Director of Inova VIP 360, Northern Virginia’s Concierge Medicine Program. He is also Regional Dean at Virginia Commonwealth University Inova Fairfax Campus.

He received his M.D. from the State University of New York at Buffalo and also attended Georgetown University, where he trained in internal medicine. He was National GRMC Chairman from 2011 to 2013.

“We remain committed to accelerating our initiatives and building robust a portfolio of compounds to address large market conditions,” Mukunda noted in the release.

The company anticipates clinical trials in 2017 for several indications, including pain, a huge market. IGC has already filed for six patents in areas such as eating disorders and epilepsy, in addition to pain. It is working on several more filings for indications including depression, Alzheimer’s and Parkinson’s disease. Its lead candidate is IGC-501, and it has filed patents for the candidate in the United States, Canada and Europe.

For more information, visit the company’s website at www.IGCinc.us